Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17108786 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL1880665 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL17108787 | 0.95 | SMN1; SMN2 (0.50) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL29934142 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2TDP1ALDH1A1KDM4ETSHR | |
| SCHEMBL29933818 | 0.83 | MC4R (0.47) | SMN1; SMN2TDP1ALDH1A1KDM4E | |
| SCHEMBL23501608 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2TDP1ALDH1A1KDM4ETSHR | |
| SCHEMBL27969917 | 0.83 | CHRNB2 (0.47) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL17095949 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2TDP1CHRNB2CHRNA4HRH3 | |
| SCHEMBL112800 | 0.83 | MC4R (0.47) | SMN1; SMN2TDP1ALDH1A1KDM4E | |
| SCHEMBL29934322 | 0.83 | HRH3 (0.47) | SMN1; SMN2HRH3ALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| CN-117209469-A | Compounds as CLK inhibitors and uses thereof | 南京圣和药物研发有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2013040215-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | SAMUMED, LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| CN-1972914-A | As histamine H3Non-imidazole heterocyclic compounds of receptor ligands | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-30 | — | — | CN | disclosed |
| EP-1761496-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005097751-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | SMN1; SMN2 3885/4885TDP1 3035/4885CHRNB2 1504/4885 |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | SMN1; SMN2 3316/4885TDP1 498/4885CHRNB2 2006/4885 |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | HRH3, HRH4, HRH1 | SMN1; SMN2 4088/4885TDP1 4213/4885CHRNB2 499/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | SMN1; SMN2 3885/4885TDP1 3035/4885CHRNB2 1504/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | SMN1; SMN2 2736/4885TDP1 3518/4885CHRNB2 2478/4885 |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | SMN1; SMN2 3426/4885TDP1 4295/4885CHRNB2 767/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | SMN1; SMN2 2603/4885TDP1 3553/4885CHRNB2 305/4885 |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | SMN1; SMN2 3426/4885TDP1 4295/4885CHRNB2 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.